Chicago, IL – According to filings with the U.S. Securities and Exchange Commission, ClostraBio is raising $10,960,833.00 in new funding. Sources indicate as part of senior management Chief Operating Officer, Brett Newswanger played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ClostraBio
Utilizing a novel polymer platform for targeted delivery of bacterial metabolites to the gut, ClostraBio is dedicated to treating food allergies and IBD. Our team is breaking new ground in treatments that restore compromised protective intestinal barrier function. We are exploring the therapeutic potential of the bacterial metabolites as treatments for immune-mediated diseases, particularly IBD and food allergy.

To learn more about ClostraBio, visit http://clostrabio.com/

Contact:
Brett Newswanger, Chief Operating Officer
717-575-3228
brett.newswanger@clostrabio.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved